文献速递泌尿男性生殖肿瘤

合并用药对初治转移性前列腺癌治疗反应与生存的影响:LATITUDE 研究的二次分析

Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study.
PubMed 文献 · Eur J Cancer · 2023-09-20

该研究为 LATITUDE 试验的二次分析,纳入 1135 例初治高危转移性前列腺癌患者,评估 7 类常用合并用药是否影响阿比特龙联合泼尼松加 ADT 的疗效。探索性分析未发现合并用药导致治疗效应存在统计学显著差异,但使用 NSAIDs 与更差的总生存和更高的前列腺癌特异性死亡独立相关。

要点

  • LATITUDE 二次分析纳入 1135 例初治高危转移性前列腺癌患者,探索性分析未发现合并用药显著改变阿比特龙治疗效应。
  • 使用 NSAIDs 与更差的总生存独立相关(HR 1.37,95%CI 1.15-1.62,p<0.001)。
  • 使用 NSAIDs 与更高的前列腺癌特异性死亡相对发生率独立相关(sHR 1.47,95%CI 1.21-1.78,p<0.001)。

核心结论

  • 该探索性分析未发现基于合并用药的初治高危转移性前列腺癌患者接受 ADT 加阿比特龙治疗效应存在统计学显著差异的证据。
  • 使用 NSAIDs 与更高的前列腺癌特异性死亡和更差的总生存独立相关。

研究设计与样本

  • LATITUDE 试验的二次分析,评估合并用药是否影响阿比特龙醋酸酯联合泼尼松加 ADT 对初治转移性前列腺癌患者总生存和前列腺癌特异性死亡的作用。
  • 共 1135 例患者符合条件,聚焦 7 类常用合并用药:二甲双胍、他汀类、质子泵抑制剂(PPIs)、环氧化酶 2(COX-2)抑制剂、阿司匹林、对乙酰氨基酚和 NSAIDs(非选择性 COX 抑制剂)。
  • 为校正多重检验,设定双侧 p<0.0024 为统计学显著性阈值。

主要发现

  • 接受合并 NSAIDs 者阿比特龙对总生存的治疗效应 HR 为 0.54(95%CI 0.42-0.70),未接受合并 NSAIDs 者为 HR 0.74(95%CI 0.60-0.91),交互作用 p=0.05,未达统计学显著。
  • 接受合并阿司匹林者阿比特龙对总生存的治疗效应 HR 为 0.93(95%CI 0.63-1.36),未接受合并阿司匹林者为 HR 0.61(95%CI 0.51-0.73),交互作用 p=0.04,为未达统计学显著的效应异质性。
  • 使用 NSAIDs 与更差的总生存独立相关(HR 1.37,95%CI 1.15-1.62,p<0.001)。
  • 使用 NSAIDs 与更高的前列腺癌特异性死亡相对发生率独立相关(sHR 1.47,95%CI 1.21-1.78,p<0.001)。

局限性

  • 该分析为探索性分析,未发现统计学显著证据表明合并用药影响 ADT 加阿比特龙的治疗效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It is unclear whether exposure to commonly prescribed medications influences survival and treatment response in patients with de novo high-risk metastatic prostate cancer (mPCa) treated with androgen receptor pathway inhibitors (ARPIs). METHODS: We performed a secondary analysis of the LATITUDE trial to determine whether receipt of concomitant medications influenced the effect of abiraterone acetate and prednisone, in addition to androgen deprivation therapy (ADT), on overall survival (OS) and prostate cancer-specific mortality (PCSM) in patients with de novo mPCa. We focused on 7 commonly prescribed classes of medications: metformin, statins, proton pump inhibitors (PPIs), cyclooxygenase 2 (COX-2) inhibitors, aspirin, acetaminophen, and NSAIDs (nonselective COX inhibitors). To account for multiple testing, a two-sided p < 0.0024 was set as the threshold for statistical significance. RESULTS: Overall, 1135 patients were eligible. There was some evidence of a differential treatment effect from abiraterone among patients who received concomitant NSAIDs (hazard ratio [HR] for OS: 0.54; 95% CI: 0.42-0.70) versus those who did not (HR: 0.74; 95% CI: 0.60-0.91), though this did not reach significance (interaction p = 0.05). A similar non-significant finding of heterogeneity of effect from abiraterone was noted among patients who received concomitant aspirin (HR for OS: 0.93 [0.63-1.36]) versus those who did not (HR: 0.61 [0.51-0.73]) (interaction p = 0.04). Receipt of NSAIDs was independently associated with a significantly inferior OS (HR: 1.37 [1.15-1.62]; p < 0.001) and higher relative incidence of PCSM (sHR: 1.47 [1.21-1.78]; p < 0.001). CONCLUSIONS: This exploratory analysis did not find statistically significant evidence of differences in treatment effects from ADT plus abiraterone in de novo high-risk mPCa based on the receipt of concurrent medications. The receipt of NSAIDs was independently associated with increased PCSM and inferior OS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roy S, Saad F, Wallis CJD, et al. Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study. Eur J Cancer. 2023. PMID: 38262848. doi:10.1016/j.ejca.2023.113348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。